

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Direct Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Journal of Clinical Pharmacology

50, 743-753

DOI: [10.1177/0091270009351883](https://doi.org/10.1177/0091270009351883)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	1.8	311
2	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. <i>Thrombosis and Haemostasis</i> , 2010, 104, 642-649.	1.8	144
3	A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2458-2468.	1.9	118
4	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2067-2076.	1.2	67
5	Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults. <i>Thrombosis Research</i> , 2010, 126, e286-e293.	0.8	23
6	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillationâ€“Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFâ€“TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2.	1.2	439
7	Laboratory assessment of new anticoagulants. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 761-772.	1.4	149
8	Edoxaban. <i>Drugs</i> , 2011, 71, 1503-1526.	4.9	98
9	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	5.0	177
10	The mechanism of action of rivaroxaban â€“ an oral, direct Factor Xa inhibitor â€“ compared with other anticoagulants. <i>Thrombosis Research</i> , 2011, 127, 497-504.	0.8	117
11	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011, 127, S5-S12.	0.8	64
12	Future of Anticoagulant Therapy. <i>Cardiovascular Therapeutics</i> , 2011, 29, 291-300.	1.1	6
13	Old and new anticoagulants. <i>Hamostaseologie</i> , 2011, 31, 21-27.	0.9	36
14	Novos anticoagulantes em cuidados intensivos. <i>Revista Brasileira De Terapia Intensiva</i> , 2011, 23, 68-77.	0.1	4
15	Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1080-1090.	1.8	37
16	Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 495-505.	1.9	7
17	Antithrombotic Therapy in Atrial Fibrillation - Evaluation and Positioning of New Oral Anticoagulant Agents -. <i>Circulation Journal</i> , 2011, 75, 1539-1547.	0.7	53
18	Pharmacotherapy of deep-venous thrombosis: current status and future perspective. <i>Clinical Investigation</i> , 2011, 1, 1039-1047.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 535-545.	1.8	103
20	How to prevent, treat, and overcome current clinical challenges of VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 265-274.	1.9	20
21	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, 130, 46-58.		90
22	New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome. <i>Pharmacotherapy</i> , 2011, 31, 975-1016.	1.2	32
23	Novel Oral Anticoagulants and Their Role in Clinical Practice. <i>Pharmacotherapy</i> , 2011, 31, 1175-1191.	1.2	37
24	Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 392-399.	1.9	12
25	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 326-343.	1.0	211
26	Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 687-694.	1.0	94
27	A Thorough Electrocardiogram Study of Edoxaban, a Novel Factor Xa Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1241-1246.	1.0	12
28	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. <i>Future Cardiology</i> , 2011, 7, 459-470.	0.5	16
29	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. <i>European Heart Journal</i> , 2011, 32, 1968-1976.	1.0	61
30	Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism. <i>Circulation</i> , 2012, 125, 159-164.	1.6	79
31	Newer Anticoagulants in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 209-221.	0.6	24
32	Novel drugs for oral anticoagulation pharmacotherapy. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 473-488.	0.6	6
33	Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2250-2255.	1.7	169
34	Clinical evidence of the role of edoxaban in anticoagulation. <i>Clinical Investigation</i> , 2012, 2, 199-206.	0.0	0
35	New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants. <i>Scientifica</i> , 2012, 2012, 1-12.	0.6	0
36	Novel anticoagulants in atrial fibrillation stroke prevention. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 123-136.	1.1	16

#	ARTICLE	IF	CITATIONS
37	New Antithrombotic Drugs. <i>Chest</i> , 2012, 141, e120S-e151S.	0.4	284
38	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 335-341.	0.8	29
39	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. <i>Journal of Cardiovascular Pharmacology</i> , 2012, Publish Ahead of Print, .	0.8	32
40	Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 925-934.	1.8	132
41	Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 1840-1847.	0.7	105
42	New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications. <i>Thrombosis and Haemostasis</i> , 2012, 108, 625-632.	1.8	64
43	Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. <i>Thrombosis Research</i> , 2012, 130, 514-519.	0.8	20
44	Management of Atrial Fibrillation: Direct Factor IIa and Xa Inhibitors or “Warfarin Shotgun”. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 705-720.	1.9	1
45	Performance of New Anticoagulants for Thromboprophylaxis in Patients Undergoing Hip and Knee Replacement Surgery. <i>Pharmacotherapy</i> , 2012, 32, 1036-1048.	1.2	4
46	In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. <i>Thrombosis Research</i> , 2012, 129, e77-e82.	0.8	62
47	To Market, To Market – 2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.5	23
48	Oral factor Xa inhibitors for the long-term management of ACS. <i>Nature Reviews Cardiology</i> , 2012, 9, 392-401.	6.1	5
49	New Oral Anticoagulants. <i>Drugs</i> , 2012, 72, 1739-1753.	4.9	76
50	Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. <i>Thrombosis and Haemostasis</i> , 2012, 108, 166-175.	1.8	36
51	Oral anticoagulation with edoxaban. <i>Hamostaseologie</i> , 2012, 32, 212-215.	0.9	19
52	Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. <i>Thrombosis and Haemostasis</i> , 2012, 108, 887-895.	1.8	15
53	Edoxaban for prevention of venous thromboembolism after major orthopedic surgery. <i>Orthopedic Research and Reviews</i> , 0, , 53.	0.7	9
54	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Novel Anticoagulants for Atrial Fibrillation. <i>Angiology</i> , 2012, 63, 164-170.	0.8	13
57	Electrochemical detection of the activities of thrombin and its inhibitor. <i>Electrochemistry Communications</i> , 2012, 16, 53-56.	2.3	18
58	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
59	Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 171-182.	0.7	20
60	Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 331-342.	1.0	179
61	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	1.0	23
62	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
63	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 208-216.	0.6	3
64	Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Drug Development Research</i> , 2013, 74, 485-491.	1.4	0
65	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013, 15, 625-651.	0.7	721
66	New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1350-1356.	0.8	10
67	Nuevos anticoagulantes orales y su papel en la prÁctica clÁnica. <i>Revista Espanola De Cardiología Suplementos</i> , 2013, 13, 33-41.	0.2	12
69	Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 245-252.	1.9	109
70	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 129-141.	0.6	36
71	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 391-398.	1.0	78
72	Synthetic approaches to the 2011 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2795-2825.	1.4	80
73	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1617-1633.	0.8	81
74	Use of New Oral Anticoagulants in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 331.	2.1	48

#	ARTICLE	IF	CITATIONS
75	Pharmacology of the new target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 133-140.	1.0	39
76	The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. <i>Thrombosis Research</i> , 2013, 131, 59-63.	0.8	54
77	Recent Advances in Antithrombotic Therapy for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 49-60.	0.5	0
78	Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. <i>Postgraduate Medicine</i> , 2013, 125, 146-157.	0.9	0
79	Treatment with novel oral anticoagulants. <i>Current Opinion in Hematology</i> , 2013, 20, 430-436.	1.2	27
80	The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 212-221.	0.8	47
81	Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants. <i>Postgraduate Medicine</i> , 2013, 125, 135-145.	0.9	6
82	Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Dawn of a New Era. <i>Postgraduate Medicine</i> , 2013, 125, 34-44.	0.9	11
83	A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 966-978.	1.1	38
84	Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 358-366.	0.8	126
85	Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1287-1294.	1.9	72
86	A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. <i>International Archive of Medicine</i> , 2013, 6, 46.	1.2	14
87	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , 2013, 9, 207.	1.0	26
88	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. <i>Thrombosis</i> , 2013, 2013, 1-10.	1.4	11
89	Clinical trials update: recent and ongoing studies in anticoagulation for atrial fibrillation. <i>Open Access Journal of Clinical Trials</i> , 0, , 101.	1.5	0
90	New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. <i>Drug Design, Development and Therapy</i> , 2014, 8, 789.	2.0	90
91	Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e95354.	1.1	6
92	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. <i>PLoS ONE</i> , 2014, 9, e99276.	1.1	33

#	ARTICLE	IF	CITATIONS
93	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?. <i>Vascular Health and Risk Management</i> , 2014, 10, 507.	1.0	21
94	The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 445-458.	1.5	6
96	Population Pharmacokinetics and Dose-Exposure Proportionality of Edoxaban in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2014, 34, 743-752.	1.1	21
97	Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1339-1351.	0.8	60
98	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. <i>Clinical Investigation</i> , 2014, 4, 619-639.	0.0	2
99	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. <i>Annals of Medicine</i> , 2014, 46, 341-352.	1.5	1
100	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Stroke</i> , 2014, 45, 2497-2505.	1.0	13
101	CardioPulse Articles. <i>European Heart Journal</i> , 2014, 35, 1825-1830.	1.0	3
102	The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. <i>Current Medical Research and Opinion</i> , 2014, 30, 2179-2190.	0.9	3
103	Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?. <i>Future Cardiology</i> , 2014, 10, 153-155.	0.5	0
104	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1526-1533.	0.7	4
105	Advantages and limitations of the new anticoagulants. <i>Journal of Internal Medicine</i> , 2014, 275, 1-11.	2.7	69
106	Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial. <i>Thrombosis Research</i> , 2014, 134, 1198-1204.	0.8	117
107	Treatment options for venous thromboembolism: lessons learnt from clinical trials. <i>Thrombosis Journal</i> , 2014, 12, 27.	0.9	18
108	Management of Hemorrhage with the Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 75-83.	0.5	0
109	Safety of new oral anticoagulant drugs: a perspective. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 8-20.	1.0	52
110	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. <i>Vascular Health and Risk Management</i> , 2014, 10, 627.	1.0	23
111	Novel Oral Anticoagulants in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 34-44.	1.0	23

#	ARTICLE	IF	CITATIONS
112	Direct Oral Anticoagulantsâ€™ Pharmacology, Drug Interactions, and Side Effects. <i>Seminars in Hematology</i> , 2014, 51, 89-97.	1.8	35
113	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. <i>International Journal of Cardiology</i> , 2014, 174, 471-483.	0.8	20
114	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	1.0	54
115	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 137-149.	1.0	25
116	Structureâ€™function relationships of factor Xa inhibitors: implications for the practicing clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 234-241.	1.0	7
117	Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 111-127.	1.0	18
118	Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies. <i>Thrombosis Research</i> , 2014, 133, 705-713.	0.8	37
119	Edoxaban Transport via P-Glycoprotein Is a Key Factor for the Drugâ€™s Disposition. <i>Drug Metabolism and Disposition</i> , 2014, 42, 520-528.	1.7	82
120	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014, 35, 1844-1855.	1.0	99
121	Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2014, 32, 74-81.	1.1	8
122	Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 15-29.	1.0	4
123	Edoxaban. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 409-416.	1.0	22
124	Oral Anticoagulant Use Around the Time of Atrial Fibrillation Ablation: A Review of the Current Evidence of Individual Oral Anticoagulant Use for Periprocedural Atrial Fibrillation Ablation Thromboembolic Prophylaxis. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1411-1418.	0.8	9
125	Treatment and Long-Term Management of Venous Thromboembolism. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 519-536.	0.7	3
126	Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. <i>Drugs</i> , 2014, 74, 1209-1231.	4.9	84
127	Ex vivo reversal of the anticoagulant effects of edoxaban. <i>Thrombosis Research</i> , 2014, 134, 909-913.	0.8	43
129	Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 247-262.	1.3	5
130	Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 372-379.	1.0	11

#	ARTICLE	IF	CITATIONS
131	The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 326.	0.4	2
132	Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. <i>European Journal of Pharmacology</i> , 2014, 742, 15-21.	1.7	12
133	The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy. <i>Current Therapeutic Research</i> , 2014, 76, 76-83.	0.5	7
134	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 79-86.	0.7	1
135	Acquired Bleeding Disorders. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 691-713.	0.5	9
136	Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan. <i>Journal of Arthroplasty</i> , 2014, 29, 2439-2446.	1.5	53
137	Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. <i>Thrombosis Research</i> , 2014, 133, 1016-1022.	0.8	81
139	Clinical Research and the Development of Medical Therapeutics. <i>Circulation Journal</i> , 2014, 78, 1267-1271.	0.7	3
140	Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1286-1292.	1.0	41
141	Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. <i>Circulation Journal</i> , 2015, 79, 1486-1495.	0.7	56
142	Population pharmacokinetics of edoxaban in patients with symptomatic deep vein thrombosis and/or pulmonary embolism—the Hokusai-VTE phase 3 study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1374-1387.	1.1	18
143	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. <i>Thrombosis Journal</i> , 2015, 13, 29.	0.9	1
144	Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1268-1279.	1.0	38
145	Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. <i>Thrombosis and Haemostasis</i> , 2015, 114, 660-669.	1.8	9
146	Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage. <i>Anesthesiology</i> , 2015, 122, 387-398.	1.3	52
147	Myths and Legends. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 255-257.	0.3	0
148	Insights into direct anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 492-498.	0.5	1
149	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. <i>Clinical Interventions in Aging</i> , 2015, 10, 1431.	1.3	20

#	ARTICLE	IF	CITATIONS
150	Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in. <i>Vascular Health and Risk Management</i> , 2015, 11, 489.	1.0	3
151	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <i>Core Evidence</i> , 2015, 10, 63.	4.7	2
152	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2015, 11, 317.	1.0	11
153	The role of factor Xa inhibitors in venous thromboembolism treatment. <i>Vascular Health and Risk Management</i> , 2015, 11, 117.	1.0	33
154	Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 719-727.	1.8	106
155	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. <i>Advances in Hematology</i> , 2015, 2015, 1-19.	0.6	11
157	Edoxaban. <i>Hospital Pharmacy</i> , 2015, 50, 619-634.	0.4	5
159	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 323-335.	1.0	9
160	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 811-824.	0.6	6
161	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. <i>Expert Review of Hematology</i> , 2015, 8, 707-725.	1.0	1
162	A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. <i>Thrombosis Journal</i> , 2015, 13, 6.	0.9	13
163	Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 288-294.	1.0	92
164	Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban. <i>American Journal of Clinical Pathology</i> , 2015, 143, 241-247.	0.4	60
165	Cancer-associated thrombosis: investigating the role of new oral anticoagulants. <i>Thrombosis Research</i> , 2015, 135, 777-781.	0.8	29
166	Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 185-97.	1.4	80
167	Target-specific oral anticoagulants and the hospitalist. <i>Hospital Practice (1995)</i> , 2015, 43, 1-12.	0.5	1
168	A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention. <i>Journal of Endovascular Therapy</i> , 2015, 22, 261-268.	0.8	16
169	Peri-procedural management of patients taking oral anticoagulants. <i>BMJ, The</i> , 2015, 351, h2391.	3.0	37

#	ARTICLE	IF	CITATIONS
170	Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 208-227.	1.5	95
171	New Oral Anticoagulants. <i>Medical Clinics of North America</i> , 2015, 99, 759-780.	1.1	5
172	Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers. <i>Thrombosis Research</i> , 2015, 135, 594-601.	0.8	4
173	New oral anticoagulants: a practical guide for physicians. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 134-145.	1.4	54
174	Edoxaban, a Novel Oral Factor Xa Inhibitor. <i>Annals of Pharmacotherapy</i> , 2015, 49, 843-850.	0.9	12
175	Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. <i>Thrombosis Research</i> , 2015, 136, 7-12.	0.8	142
176	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 937-948.	1.5	4
177	Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 117-122.	0.5	5
178	Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. <i>Circulation</i> , 2015, 131, 82-90.	1.6	240
179	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2015, 10, 555-560.	1.0	11
180	Edoxaban: A Review in Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 351-361.	1.0	5
181	Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 367-376.	0.6	1
182	The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults. <i>Clinical Drug Investigation</i> , 2015, 35, 447-453.	1.1	66
183	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
184	The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. <i>Thrombosis Research</i> , 2015, 136, 825-831.	0.8	32
185	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2661-2678.	0.9	4
186	Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. <i>Drugs</i> , 2015, 75, 2025-2034.	4.9	4
187	The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. <i>Current Medical Research and Opinion</i> , 2015, 31, 197-210.	0.9	11

#	ARTICLE	IF	CITATIONS
188	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 10-20.	1.0	33
189	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	1.8	11
190	Risk impact of edoxaban in the management of stroke and venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 329-335.	1.0	4
191	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. <i>Vascular Health and Risk Management</i> , 2016, 12, 45.	1.0	4
192	Use of novel oral anticoagulant agents in venous thromboembolism. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 570-581.	0.7	17
193	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. <i>Emergency Medicine International</i> , 2016, 2016, 1-13.	0.3	22
194	Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 667.	0.9	0
195	The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective. <i>Hospital Pharmacy</i> , 2016, 51, 26-34.	0.4	0
196	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	1.2	79
197	Management of direct oral anticoagulants-associated bleeding in the trauma patient. <i>Current Opinion in Anaesthesiology</i> , 2016, 29, 220-228.	0.9	16
198	Novel oral anticoagulants in the management of coronary artery disease. <i>Coronary Artery Disease</i> , 2016, 27, 412-419.	0.3	4
199	Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 516-523.	0.6	5
201	Dosage plasmatique de quatre anticoagulants directs par UHPLC/DAD. <i>Toxicologie Analytique Et Clinique</i> , 2016, 28, 278-285.	0.1	0
202	Edoxab�n. Propiedades farmacocin�ticas y farmacodin�micas. <i>Revista Espanola De Cardiologia Suplementos</i> , 2016, 16, 60-66.	0.2	2
203	A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. <i>American Journal of the Medical Sciences</i> , 2016, 352, 92-106.	0.4	21
204	Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin�K Antagonist Oral Anticoagulant that Inhibits Clotting Factor�Xa. <i>Clinical Pharmacokinetics</i> , 2016, 55, 641-655.	1.6	160
205	Consideraciones cl�nicas sobre la posolog�a de los anticoagulantes orales de acci�n directa. <i>Revista Clinica Espanola</i> , 2016, 216, 384-392.	0.2	0
206	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 566-572.	1.0	6

#	ARTICLE	IF	CITATIONS
207	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s14-s26.	0.5	15
208	Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants. <i>Air Medical Journal</i> , 2016, 35, 148-155.	0.3	16
209	Overview of direct oral anticoagulant therapy reversal. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s5-s13.	0.5	13
210	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
211	Minimizing the Risk of Bleeding with NOACs in the Elderly. <i>Drugs and Aging</i> , 2016, 33, 491-500.	1.3	36
212	Establishing Edoxaban's Role in Anticoagulation. <i>Journal of Pharmacy Practice</i> , 2016, 29, 228-238.	0.5	3
213	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <i>American Journal of Medicine</i> , 2016, 129, S33-S40.	0.6	74
214	Novel oral anticoagulants in non-valvular atrial fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. <i>International Journal of the Cardiovascular Academy</i> , 2016, 2, 167-173.	0.1	4
215	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016, 34, 3-8.	0.7	25
216	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. <i>International Journal of Cardiology</i> , 2016, 225, 154-158.	0.8	0
217	Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism. <i>Heart</i> , 2016, 102, 975-983.	1.2	10
218	Clinical considerations on the posology of direct oral anticoagulants. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2016, 216, 384-392.	0.3	0
219	Upstream versus downstream thrombin inhibition. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1273-1282.	0.6	4
220	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillationâ€œ An ENGAGE AF-TIMI 48 Subanalysis â€œ. <i>Circulation Journal</i> , 2016, 80, 860-869.	0.7	83
221	Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2016, 80, 745-747.	0.7	4
222	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36.	1.6	234
223	Efficacy Study of the COmbination of Edoxaban and Physiotherapy on the PREvention of Venous-Thromboembolism in patients after Total Knee Arthroplasty (ESCORT-TKA Trial): Study protocol for a randomized controlled trial. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2016, 19, 1-4.	1.0	3
224	Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. <i>International Journal of Hematology</i> , 2016, 103, 665-672.	0.7	6

#	ARTICLE	IF	CITATIONS
225	Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences. <i>Journal of Intensive Care</i> , 2016, 4, 19.	1.3	36
226	Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. <i>Journal of Pharmacy Practice</i> , 2016, 29, 392-405.	0.5	2
227	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	1.3	18
228	Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etxilate in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2016, 36, 127-136.	1.1	3
229	Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 24.	0.4	3
230	Management of Venous Thromboembolism. <i>Annals of Pharmacotherapy</i> , 2016, 50, 486-501.	0.9	21
231	Periprocedural Management of Antithrombotic Agents. , 2016, , 9-32.		0
232	A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation. <i>Thrombosis Research</i> , 2016, 141, 77-83.	0.8	15
233	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 (ENGAGE AF—TIMI 48) trial. <i>American Heart Journal</i> , 2016, 172, 144-151.	1.2	13
234	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 163-176.	0.6	8
235	Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 241-247.	1.0	61
236	Effects of feed deprivation on the AMPK signaling pathway in skeletal muscle of broiler chickens. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2016, 191, 146-154.	0.7	16
237	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <i>International Journal of Cardiology</i> , 2016, 202, 578-585.	0.8	34
238	Novel oral anticoagulants and the 73rd anniversary of historical warfarin. <i>Journal of the Saudi Heart Association</i> , 2016, 28, 31-45.	0.2	13
239	Edoxaban in patients with atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 81-90.	1.0	4
240	Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 677-684.	0.7	13
242	Edoxaban: A direct oral anticoagulant. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 117-129.	0.5	33
243	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	1.0	44

#	ARTICLE	IF	CITATIONS
244	Novel (Oral) Anticoagulant Challenges in Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 706-715.	1.5	5
245	Novel Anticoagulant Agents in the Perioperative Setting. <i>Anesthesiology Clinics</i> , 2017, 35, 305-313.	0.6	9
246	Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 423-432.	1.5	22
247	Peri-procedural use of anticoagulants in radiology: an evidence-based review. <i>Abdominal Radiology</i> , 2017, 42, 1556-1565.	1.0	13
248	Direct Oral Anticoagulants: An Overview for the Interventional Radiologist. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 321-330.	0.9	5
249	Acquired Bleeding Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1123-1145.	0.9	13
250	Common Pharmacologic Issues. , 2017, , 405-414.		0
251	Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. <i>Techniques in Vascular and Interventional Radiology</i> , 2017, 20, 141-151.	0.4	6
252	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1325-1332.	0.9	23
254	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 113-122.	1.5	5
255	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 5-15.	1.3	3
256	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , 2017, 40, 46-52.	0.7	25
257	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. <i>Clinical Cardiology</i> , 2017, 40, 126-131.	0.7	21
258	Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 301-318.	0.7	52
259	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30 mg in healthy Chinese volunteers. <i>Xenobiotica</i> , 2017, 47, 592-599.	0.5	3
260	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , 2017, 31, 77-84.	2.8	133
261	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.4	245
262	Pharmacological profile of non-vitamin K antagonist oral anticoagulants. <i>African Journal of Pharmacy and Pharmacology</i> , 2017, 11, 125-136.	0.2	4

#	ARTICLE	IF	CITATIONS
263	Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation. <i>Hamostaseologie</i> , 2017, 37, 277-285.	0.9	2
264	Drug-induced liver injury: Towards early prediction and risk stratification. <i>World Journal of Hepatology</i> , 2017, 9, 30.	0.8	22
265	Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 835-843.	0.8	9
266	Transitioning Between Anticoagulants. , 2018, , 133-150.		0
267	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018, 118, 437-450.	1.8	268
268	Recomendaciones del Grupo Catal�n de Trombosis (Tromboc@t Working Group) para el tratamiento de los pacientes que reciben anticoagulantes orales directos. <i>Medicina Cl�nica</i> , 2018, 151, 210.e1-210.e13.	0.3	2
269	Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges. <i>American Journal of the Medical Sciences</i> , 2018, 355, 467-476.	0.4	5
270	Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. <i>Regional Anesthesia and Pain Medicine</i> , 2018, 43, 263-309.	1.1	596
271	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
272	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, 51-58.	1.8	110
273	An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 221-228.	1.6	21
274	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
275	Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018, 2, 1066-1075.	2.5	10
276	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. <i>Journal of the American Heart Association</i> , 2018, 7, e010854.	1.6	7
277	Edoxaban for Venous Thromboembolism Treatment��The New Kid on The Block for Latin America. A Practical Guide. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 340S-349S.	0.7	4
278	Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. <i>Medicina Cl�nica (English Edition)</i> , 2018, 151, 210.e1-210.e13.	0.1	0
279	Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 575-583.	0.6	13
280	Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 2421-2429.	1.0	42

#	ARTICLE	IF	CITATIONS
281	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. <i>International Urology and Nephrology</i> , 2018, 50, 1633-1642.	0.6	3
282	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
284	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). <i>Pharmacological Research</i> , 2018, 135, 60-79.	3.1	81
285	The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2018, 28, 1349-1358.	0.6	3
286	Anticoagulation at the extremes of body weight: choices and dosing. <i>Expert Review of Hematology</i> , 2018, 11, 817-828.	1.0	21
287	Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update. <i>Medicines (Basel)</i> , 2019, 10, 107.	0.7	31
288	Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. <i>International Journal of Medical Sciences</i> , 2019, 16, 1295-1303.	1.1	22
289	Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. <i>Thrombosis Research</i> , 2019, 175, 61-67.	0.8	12
290	Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism—An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan). <i>Circulation Journal</i> , 2019, 83, 1394-1404.	0.7	7
291	Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1155-1163.	1.6	12
292	In vitro assessment of edoxaban anticoagulant effect in pediatric plasma. <i>Thrombosis Research</i> , 2019, 178, 112-118.	0.8	6
293	A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 103-110.	1.0	8
294	Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 313-320.	1.0	5
295	Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results. <i>Journal of Arrhythmia</i> , 2019, 35, 121-129.	0.5	7
296	Venous thromboembolism prevention through the use of novel Factor Xa inhibitors. <i>Postgraduate Medicine</i> , 2019, 131, 89-95.	0.9	1
297	How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 285-286.	0.8	5
298	Insight into the perioperative management of direct oral anticoagulants: concerns and considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 465-472.	0.9	2
299	Pharmacology of Oral Anticoagulants. , 2019, , 11-34.		2

#	ARTICLE	IF	CITATIONS
300	Outpatient Oral Anticoagulant Therapy. , 2019, , 747-777.		1
301	Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 94-99.	1.0	2
302	Ginsenoside Rg1 Induces Apoptotic Cell Death in Triple-Negative Breast Cancer Cell Lines and Prevents Carcinogen-Induced Breast Tumorigenesis in Sprague Dawley Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	15
303	Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan. <i>Thrombosis Research</i> , 2020, 195, 158-164.	0.8	6
304	Pharmacokinetic-Pharmacodynamic Analysisâ€™™ Role in Design of Phase â€¦Clinical Trials of Anticoagulant Agents: A Systematic Review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1191-1202.	1.3	0
305	Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1146, 122121.	1.2	4
306	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020, 80, 1065-1083.	4.9	22
307	Use of Direct Oral Anticoagulants in Children and Adolescents. <i>Hamostaseologie</i> , 2020, 40, 064-073.	0.9	17
308	Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 718-723.	1.0	5
309	Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment. <i>Clinical Drug Investigation</i> , 2020, 40, 567-573.	1.1	5
310	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Advances in Hematology</i> , 2020, 2020, 1-10.	0.6	24
311	Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 102-111.	1.0	8
312	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 505-519.	1.3	14
313	Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021, 12, 138-147.	0.6	7
314	Consider clinically relevant drug interactions when prescribing edoxaban. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 115-119.	0.3	0
315	Pharmacogenetics of Direct Oral Anticoagulants. , 0, , .		3
316	Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 52.	0.4	2
317	Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1061-1071.	1.6	4

#	ARTICLE	IF	CITATIONS
318	Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants. <i>Biomedicines</i> , 2021, 9, 264.	1.4	10
319	Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). <i>Biomedicines</i> , 2021, 9, 445.	1.4	39
320	Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. <i>Biomedicines</i> , 2021, 9, 451.	1.4	20
321	Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats. <i>TH Open</i> , 2021, 05, e107-e112.	0.7	0
322	Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0249940.	1.1	14
323	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
324	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Advances in Therapy</i> , 2021, 38, 2891-2907.	1.3	7
325	Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021, 71, 429-442.	0.2	2
326	Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency. <i>Thrombosis Journal</i> , 2021, 19, 50.	0.9	4
327	Edoxaban in Cardiovascular Disease Management: Review. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	2
328	Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 736826.	1.6	3
329	Management of risk factors for gastrointestinal bleeding in patients receiving anticoagulant therapy. <i>Russian Journal of Cardiology</i> , 2021, 26, 4635.	0.4	4
330	Pharmacokinetics and Pharmacodynamics of DOAC. , 2021, , 27-40.		0
331	Determination of Edoxaban in Bulk and in Tablet Dosage Form by Stability Indicating High-Performance Liquid Chromatography. <i>Pharmaceutical Sciences</i> , 2016, 22, 35-41.	0.8	7
332	The Potential Role of Edoxaban in Stroke Prevention Guidelines. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 40-43.	1.3	2
334	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. <i>Journal of Thoracic Disease</i> , 2015, 7, 165-71.	0.6	44
335	Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors. <i>World Journal of Neuroscience</i> , 2012, 02, 7-14.	0.1	4
336	Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Cardiovascular Medicine(Switzerland)</i> , 2013, 16, 103-114.	0.1	7

#	ARTICLE	IF	CITATIONS
337	New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World Journal of Orthopedics, 2014, 5, 188.	0.8	5
338	2. Pharmacokinetics and Drug Interaction of New Anticoagulants: Direct Thrombin Inhibitor and Factor Xa Inhibitors. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 305-313.	0.1	0
340	Anticoagulation for Venous Thromboembolism. , 2014, , 293-307.		0
342	Pharmacological characteristics of novel oral anticoagulant drugs for thromboprophylaxis in atrial fibrillation. Srce I Krvni Sudovi, 2014, 33, 179-186.	0.1	0
343	Road to selection of edoxaban as an oral factor Xa inhibitor. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 369-375.	0.1	0
345	Advances in Anticoagulants. , 2016, , 819-825.		0
346	Oral Anticoagulants. , 2016, , 1-16.		0
347	Risk management of direct oral anticoagulant administration: An approach from the clinical laboratory. Tenri Medical Bulletin, 2016, 19, 81-89.	0.1	0
348	Direct Thrombin Inhibitors. , 2016, , 7-24.		0
349	Oral Anticoagulants. , 2017, , 1325-1339.		0
351	Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3274-3281.	0.2	1
352	Intracerebral hemorrhage after thrombolysis with recombinant tissue plasminogen activator in a patient treated with edoxaban. Nosotchu, 2019, 41, 299-303.	0.0	0
353	A Clinically Oriented Review of the Landmark Clinical Trials Comparing Warfarin and Aspirin to Novel Oral Anticoagulants in Atrial Fibrillation. , 2019, 1, 1-5.		0
354	The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation. Atherothrombosis, 2020, , 28-43.	0.1	0
355	Non- Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Journal of Cardiovascular Pharmacology, 2021, 77, 11-21.	0.8	6
356	Improving anticoagulation management in patients with atrial fibrillation. P and T, 2013, 38, 173-7.	1.0	0
357	Edoxaban: an investigational factor xa inhibitor. P and T, 2014, 39, 686-715.	1.0	1
358	Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. Journal of Atrial Fibrillation, 2015, 8, 1218.	0.5	2

#	ARTICLE	IF	CITATIONS
359	DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF EDOXABAN TOSYLATE IN TABLET DOSAGE FORMS. <i>Indian Drugs</i> , 2020, 57, 47-51.	0.1	0
360	Mechanisms of action of new oral coagulants. <i>IzvestiĀ Rossijskoj Voenno-meditsinskoj Akademii</i> , 2021, 40, 33-40.	0.1	0
361	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787235.	1.1	4
362	Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis. <i>BMJ Open</i> , 2022, 12, e048619.	0.8	3
363	Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation. <i>Minerva Cardiology and Angiology</i> , 2022, , .	0.4	2
364	The effect of contrast agents on the anticoagulant properties of oral factor Xa inhibitors. <i>Acta Radiologica</i> , 2022, , 028418512210814.	0.5	0
365	Biopharmaceutics considerations for direct oral anticoagulants. <i>Drug Development and Industrial Pharmacy</i> , 2022, , 1-53.	0.9	0
366	Efficacy and safety of edoxaban tosylate hydrate 15Åmg in the prevention of venous thromboembolism in patients with impaired renal function after orthopedic surgery of the lower extremities. <i>Renal Replacement Therapy</i> , 2021, 7, .	0.3	0
367	New Oral Anticoagulant Versus Vitamin K Antagonists for Thoracoscopic Ablation in Patients With Persistent Atrial Fibrillation: A Randomized Controlled Trial. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.4	2
369	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. <i>Pharmaceutics</i> , 2022, 14, 1120.	2.0	29
370	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	2.1	13
371	Mitral valve repair with patch augmentation for atrial functional mitral regurgitation complicated with giant left atrium. <i>General Thoracic and Cardiovascular Surgery</i> , 0, , .	0.4	0
372	Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 1440-1446.	0.8	1
373	Evaluation of bleeding and anticoagulation markers by edoxaban and lowâ€dose cyclosporine: A case series study. <i>Biopharmaceutics and Drug Disposition</i> , 0, , .	1.1	0
374	Direct oral anticoagulants (DOACs): From the laboratory point of view. <i>Acta Pharmaceutica</i> , 2022, 72, 459-482.	0.9	2
375	Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	0
376	Ensuring safety of Novel Oral Anticoagulants Predictable Dose Response Relationship. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 4812-4818.	0.2	0
377	The importance of renal function in anemic patients treated with edoxaban after orthopedic surgery in a real-world clinical setting: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31298.	0.4	0

#	ARTICLE	IF	CITATIONS
378	Gut microbiota and cardiac arrhythmia: a pharmacokinetic scope. Egyptian Heart Journal, 2022, 74, .	0.4	0
379	Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness. Journal of Clinical Medicine, 2023, 12, 860.	1.0	0
380	Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. Clinical Pharmacokinetics, 2023, 62, 351-373.	1.6	5